A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study of EVO301 in Adults With Atopic Dermatitis
Status: Completed
Location: See all (12) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a Phase 2a efficacy and safety study of EVO301 for the treatment of adults with atopic dermatitis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Males or non-pregnant, non-lactating females, age 18 years or older
• Chronic atopic dermatitis for at least 6 months
• BSA of AD involvement of at least 10%
• EASI score of at least 16.
Locations
Other Locations
Australia
Cornerstone Dermatology
Coorparoo
Momentum Clinical Research Darlinghurst
Darlinghurst
New Zealand
Optimal Clinical Trials
Auckland
Optimal Clinical Trials North
Auckland
Pacific Clinical Research Network (PCRN) Auckland
Auckland
Pacific Clinical Research Network (PCRN) Christchurch
Christchurch
Momentum Clinical Research Dunedin
Dunedin
Clinical Trials New Zealand Ltd
Hamilton
Momentum Clinical Research Lower Hutt
Hutt Central
Pacific Clinical Research Network (PCRN) Tasman
Nelson
Momentum Clinical Research Kapiti
Paraparaumu
Momentum Clinical Research Pukekohe
Pukekohe
Time Frame
Start Date: 2025-02-13
Completion Date: 2025-11-17
Participants
Target number of participants: 71
Treatments
Experimental: Intravenous EVO301
Placebo_comparator: Placebo
Related Therapeutic Areas
Sponsors
Leads: Evommune, Inc.